CA3029004A1 - Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer - Google Patents
Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer Download PDFInfo
- Publication number
- CA3029004A1 CA3029004A1 CA3029004A CA3029004A CA3029004A1 CA 3029004 A1 CA3029004 A1 CA 3029004A1 CA 3029004 A CA3029004 A CA 3029004A CA 3029004 A CA3029004 A CA 3029004A CA 3029004 A1 CA3029004 A1 CA 3029004A1
- Authority
- CA
- Canada
- Prior art keywords
- exemplary embodiment
- compound
- unsubstituted
- formula
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(Cc1c(C)nc(N***)[n]1)[U] Chemical compound CC(Cc1c(C)nc(N***)[n]1)[U] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354449P | 2016-06-24 | 2016-06-24 | |
| US62/354,449 | 2016-06-24 | ||
| US201662426095P | 2016-11-23 | 2016-11-23 | |
| US62/426,095 | 2016-11-23 | ||
| PCT/US2017/039119 WO2017223516A1 (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3029004A1 true CA3029004A1 (en) | 2017-12-28 |
| CA3029004C CA3029004C (en) | 2025-09-09 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018015893A (es) | 2019-08-01 |
| ES2964531T3 (es) | 2024-04-08 |
| SG11201811393WA (en) | 2019-01-30 |
| US20190337928A1 (en) | 2019-11-07 |
| KR102494294B1 (ko) | 2023-01-31 |
| CN109843874A (zh) | 2019-06-04 |
| BR112018076821A2 (pt) | 2019-04-02 |
| IL263917A (en) | 2019-02-28 |
| AU2017280334A1 (en) | 2019-01-17 |
| JP2019522681A (ja) | 2019-08-15 |
| ZA202301066B (en) | 2024-05-30 |
| PL3475272T3 (pl) | 2024-04-29 |
| US20190352283A1 (en) | 2019-11-21 |
| KR20190033534A (ko) | 2019-03-29 |
| US11072600B2 (en) | 2021-07-27 |
| IL263917B (en) | 2022-07-01 |
| US10640493B2 (en) | 2020-05-05 |
| EP3475272B1 (en) | 2023-09-13 |
| US20220402894A1 (en) | 2022-12-22 |
| HUE066216T2 (hu) | 2024-07-28 |
| JP2022037004A (ja) | 2022-03-08 |
| US12145925B2 (en) | 2024-11-19 |
| CN109843874B (zh) | 2022-05-27 |
| AU2017280334C1 (en) | 2022-10-20 |
| AU2017280334B2 (en) | 2021-07-29 |
| MX2021013641A (es) | 2022-01-06 |
| EP3475272A1 (en) | 2019-05-01 |
| WO2017223516A1 (en) | 2017-12-28 |
| MX387726B (es) | 2025-03-18 |
| PT3475272T (pt) | 2023-12-15 |
| ZA201808562B (en) | 2023-12-20 |
| JP7033588B2 (ja) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12145925B2 (en) | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | |
| CA2759241C (en) | Novel anti-inflammatory agents | |
| US10202360B2 (en) | Therapeutic compounds | |
| WO2016131381A1 (en) | Fused-ring compounds, pharmaceutical composition and uses thereof | |
| WO2006024837A1 (en) | Isoindolin-1-one derivatives | |
| CN118005656A (zh) | Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用 | |
| KR20170035944A (ko) | PI3K, mTOR 저해제로서 융합된 퀴놀린 화합물 | |
| TW580498B (en) | A novel amide compound and a pharmaceutical composition containing the same | |
| US11708352B2 (en) | Anti-cancer compounds | |
| CA3135921C (en) | Quinolyl-containing compound and pharmaceutical composition, and use thereof | |
| AU2008252628A1 (en) | Bicyclosulfonyl acid (BCSA) compounds and their use as therapeutic agents | |
| KR20190125367A (ko) | 아제티딘 유도체 | |
| CA3029004C (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| HK40002445B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| HK40002445A (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| CN111630048B (zh) | 脒类和胍类衍生物、其制备方法及其在医药上的应用 | |
| BR112018076821B1 (pt) | Compostos ou sal, hidrato ou solvato dos mesmos, seus usos, formulação farmacêutica e método in vitro de inibição de parp1 e/ou parp2 e/ou tubulina | |
| WO2025215187A1 (en) | Therapeutic compounds and their use | |
| WO2025240834A1 (en) | Nsd2-targeted chemical degraders and compositions and methods of use thereof | |
| WO2025242880A1 (en) | Therapeutic compounds and their use | |
| CN103052641B (zh) | 作为c‑Met抑制剂的新型稠环杂环衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |